Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:16:53 EDT Sun 13 Sep 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:TRAW - TRAWS PHARMA INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TRAW - Q0.50.50·0.6460.10.5643+0.03286.284.4322140.5301  0.5896  0.52313.25  0.430119:53:53Aug 1415 min RT 2¢

Recent Trades - Last 10 of 214
Time ETExPriceChangeVolume
19:53:53Q0.57750.04670
19:30:07Q0.56430.03281
16:12:31Q0.55020.01871
16:10:42Q0.55010.018610
16:10:05Q0.56430.03281
16:10:04Q0.56430.03281
16:10:04Q0.56430.03281
16:09:24Q0.550.01851
16:04:07Q0.56430.03281
16:04:07Q0.56430.03281

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-08-14 16:30U:TRAWNews ReleaseTraws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
2026-06-22 07:00U:TRAWNews ReleaseTraws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
2026-06-12 17:30U:TRAWNews ReleaseTraws Pharma Provides Regulatory Update on Influenza Program
2026-05-27 08:45U:TRAWNews ReleaseTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
2026-05-15 07:00U:TRAWNews ReleaseTraws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
2026-05-08 07:30U:TRAWNews ReleaseTraws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
2026-04-15 16:01U:TRAWNews ReleaseTraws Pharma Reports Full Year 2025 Results and Provides Business Highlights
2026-04-15 08:15U:TRAWNews ReleaseTraws Pharma Announces Up to $60 Million Private Placement Financing
2026-02-19 07:30U:TRAWNews ReleaseTraws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID(TM)-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
2026-01-26 08:30U:TRAWNews ReleaseTraws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID(TM)-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
2026-01-13 07:00U:TRAWNews ReleaseTraws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID(TM)-Eligible and Ineligible COVID-19 Patients
2025-12-17 06:00U:TRAWNews ReleaseTraws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID(TM), Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
2025-11-13 07:00U:TRAWNews ReleaseTraws Pharma Reports Third Quarter 2025 Results and Business Highlights
2025-10-30 12:00U:TRAWNews ReleaseChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
2025-10-22 18:40U:TRAWNews ReleaseDover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
2025-10-14 07:00U:TRAWNews ReleaseTraws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
2025-10-06 07:00U:TRAWNews ReleaseTraws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
2025-09-25 07:30U:TRAWNews ReleaseAnnovis Appoints Mark Guerin as Chief Financial Officer